Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YKP-1358
- Development stage
- Discontinued
- Lead developer
- SK Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YKP-1358 is a novel investigational atypical antipsychotic small molecule developed by SK Biopharmaceuticals Co., Ltd. It functions as an antagonist at serotonin 5-HT2A and 5-HT2C receptors, and dopamine D2 and D3 receptors. Preclinical studies indicated its potential efficacy in treating both positive and negative symptoms of schizophrenia with a low propensity for extrapyramidal side effects. It progressed to Phase 1 clinical trials for schizophrenia in the United States before its development was discontinued.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on YKP-1358.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YKP-1358.